ArticleReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2026
Hypofractionated chemoradiotherapy for non-small-cell lung cancer in a real-world setting: a single-centre experience.
Article in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to evaluate tolerability and outcomes of hypofractionated radiotherapy for non-small cell lung cancer (NSCLC), with or without concomitant or prior chemotherapy, in a real-world single-centre setting. Materials and methods: Between August 2017 and September 2024, 117 consecutive NSCLC patients treated with hypofractionated radiotherapy were prospectively registered. The predominant regimen was 55 Gy in 20 fractions (94.1%), delivered either concurrently or after chemotherapy. Results: A total of 102 patients were analysed: 6 had stage II, 82 had stage III, and 14 had stage IV disease. Fifty-nine patients received concurrent chemoradiotherapy (conc-RChT) and 43 sequential chemotherapy followed by radiotherapy (seq-RChT). Median disease-free and overall survival were 18.3 and 22.0 months, respectively. Eastern Cooperative Oncology Group (ECOG) performance status was the only independent prognostic factor for overall survival (30.3 months for ECOG 0 Conclusions: To our knowledge, this is the first large real-world series from our country including unselected NSCLC patients treated with hypofractionated radiotherapy. Although 55 Gy in 20 fractions is standard in the UK, its use remains limited locally, particularly with conc-RChT. Our findings support hypofractionation as an effective and well-tolerated option, especially in high-volume centres.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.